Tranzone secures GSK deal

Published: 8-Dec-2011
Finance Logistics

Will store various products in Jebel Ali for distribution to the Gulf and Near East Region

Tranzone Logistics, a subsidiary of Saudia Arabia-based Banaja Holdings, is to store various products for GlaxoSmithKline in its new warehouse in Jebel Ali for distribution to the Gulf and Near East Region.

The deal was signed during the opening ceremony for Tranzone’s new facility.

GSK will occupy a major part of Tranzone’s warehouse, contributing approximately 25% of revenue in 2012.

Tranzone said GSK had demanded top-of-the-range facilities and back up to protect products at all times and in all circumstances. Emphasis had also been placed on physical security such as access control and fire prevention and process quality.

Tranzone’s state-of-the-art 3PL warehouse at JAFZA in Jebel Ali provides storage, inventory management, as well as purchasing and re-invoicing to the distributor, all at one convenient location. The firm says it is able to store pharmaceuticals in an ideal environment, and its integrated system better links principals with distributors, removes layers of inefficiency and cuts costs while improving service quality.

See more

You may also like

Manufacturing

Banaja takes majority stake in DEEF Pharmaceutical

Read more
Aims to expand and diversify DEEF facility in Saudi Arabia

Trending Articles

  1. BioNTech to cut up to 1860 jobs and end COVID vaccine production in Germany The German biotech has announced it will cease production at its manufacturing sites in Germany and Singapore in its Q1 earnings report, cutting up to 22% of its workforce in the process as it pivots from COVID-19 vaccines to oncology
  2. Novo Nordisk raises 2026 guidance after Wegovy pill drives stronger-than-expected Q1 earnings The firm has reported first-quarter earnings of $7.61bn and revenue of $15.17bn, both ahead of Wall Street forecasts, driven by robust GLP-1 sales and stronger-than-expected performance from its oral Wegovy pill
  3. Oncodesign Services extends GIP ARRONAX collaboration to secure astatine-211 supply The company has extended its collaboration with the French radionuclide specialist to secure access to astatine-211, an alpha-emitting radioisotope of growing interest in targeted radiotherapy but constrained by its seven-hour half-life and limited production capacity
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    AstraZeneca resumes £300m UK investment as drug pricing and tariff landscape shifts The Cambridge and Macclesfield programmes, paused amid NHS reimbursement disputes, are back on track following the US-UK pharmaceutical deal and a revised NHS rebate rate
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Britain's biotech potential (part II): world-class science, second-class support? In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale

Upcoming event

CHEMUK 2026

20–21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Banaja takes majority stake in DEEF Pharmaceutical

Aims to expand and diversify DEEF facility in Saudi Arabia
Manufacturing

Former Catalent Chair and CEO George Fotiades joins eXmoor Pharma board as Chair

Angela Osborne steps back from operational duties and continues as Founder and Board Director, providing strategic continuity as eXmoor builds the leadership depth to support its expanding integrated CDMO model
Manufacturing

BioNTech to cut up to 1860 jobs and end COVID vaccine production in Germany

The German biotech has announced it will cease production at its manufacturing sites in Germany and Singapore in its Q1 earnings report, cutting up to 22% of its workforce in the process as it pivots from COVID-19 vaccines to oncology
Finance

Novo Nordisk raises 2026 guidance after Wegovy pill drives stronger-than-expected Q1 earnings

The firm has reported first-quarter earnings of $7.61bn and revenue of $15.17bn, both ahead of Wall Street forecasts, driven by robust GLP-1 sales and stronger-than-expected performance from its oral Wegovy pill
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

AstraZeneca resumes £300m UK investment as drug pricing and tariff landscape shifts

The Cambridge and Macclesfield programmes, paused amid NHS reimbursement disputes, are back on track following the US-UK pharmaceutical deal and a revised NHS rebate rate
Finance

BASF reports Q1 earnings as currency headwinds and Middle East conflict weigh on revenue

The German chemicals giant posted solid volume growth across most segments in the first quarter of 2026, but adverse currency effects eroded sales and pushed EBITDA before special items down
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Britain's biotech potential (part II): world-class science, second-class support?

In part one, Manufacturing Chemist explored the UK’s world-class science base and early-stage investment appeal. In this second instalment, attention turns to the structural gaps that are limiting its ability to scale
Subscribe now